Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years

Harpaz, Rafael; Hales, Craig M.; Bialek, Stephanie R.
November 2011
MMWR: Morbidity & Mortality Weekly Report;11/11/2011, Vol. 60 Issue 44, p1528
The article reports that the U.S. Food and Drug Administration (FDA) has agreed for the use of Zostavax for the vaccination of adults aged 50 through 59 years. It mentions that herpes zoster vaccine was licensed and approved in 2006 for prevention of herpes zoster among old people. It also suggests that postherpetic neuralgia symptoms should be considered seriously while serving the patient by the Zostavax vaccination which is attributable to preexisting chronic pain, and severe depression.


Related Articles

  • Can Shingles Be Prevented?  // Shingles: Hope through Research (NINDS);May2010, p7 

    The article offers information on the prevention of shingles. It mentions the varicella-zoster virus (VZV) vaccine, Zostavax, for the prevention of shingles in people over 60 who have had chickenpox, which has been approved by the U.S. Food and Drug Administration (FDA). It is mentioned that...

  • Herpes Zoster Vaccination in People Aged 50-59 Years. Hong-tian Li; Shichao Lu; Jian-meng Liu // Clinical Infectious Diseases;4/1/2012, Vol. 54 Issue 7, p929 

    The article presents information on the herpes zoster vaccination in the people of age between 50 and 59 Years. It states that Herpes zoster caused by reactivation of latent varicella-zoster virus (VZV) in the dorsal root or cranial nerve ganglia manifests as unilateral acute pain accompanied by...

  • Efficacy and Safety Data for ZOSTAVAX(r) (Zoster Vaccine Live), Merck's Shingles Vaccine, in Adults Ages 50-59 Published in Clinical Infectious Diseases.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article focuses on the Zostavax, a live vaccine developed by Merck and Co., pharmaceutical companies, is reducing the incidence of shingles in a study of adults aged 50-59 who received the vaccine published in the journal "Clinical Infectious Diseases." It mentions that Zostavax was approved...

  • Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. Hung Fu Tseng; Bruno Lewin; Hales, Craig M.; Sy, Lina S.; Harpaz, Rafael; Bialek, Stephanie; Yi Luo; Jacobsen, Steven J.; Reddy, Kavya; Po-yin Huang; Jeff Zhang; Anand, Sean; Bauer, Erin Mary; Jennifer Chang; Tartof, Sara Y.; Tseng, Hung Fu; Lewin, Bruno; Luo, Yi; Huang, Po-Yin; Zhang, Jeff // Journal of Infectious Diseases;10/15/2015, Vol. 212 Issue 8, p1222 

    Background: Although it is evident that zoster vaccination reduces postherpetic neuralgia (PHN) risk by reducing herpes zoster (HZ) occurrence, it is less clear whether the vaccine protects against PHN among patients who develop HZ despite previous vaccination.Methods:...

  • FDA Approves Zostavax Vaccine to Prevent Shingles in Individuals 50 to 59 Years of Age.  // Clinical Infectious Diseases;6/1/2011, Vol. 52 Issue 11, preceding p1343 

    The article reports that the U.S. Food and Drug Administration has approved the use of Zostavax vaccine, for the prevention of Shingles in individuals aged between 50 to 59 years in the U.S., also, Zostavax is a live attenuated virus vaccine and was already used in individuals aged above 60 years.

  • Response to Dr Clearkin. Williams, G; Olson, J A // Eye;Dec2014, Vol. 28 Issue 12, p1523 

    A reply to the letter to the editor in response to an article about the implementation of shingles vaccine in Great Britain is presented.

  • Lidocaine patch approved for postherpetic neuralgia. Maudlin, Robert K. // Modern Medicine;Jun99, Vol. 67 Issue 6, p51 

    Reports on the approval made by the United States Food and Drug Administration on a lidocaine patch (Lidoderm) to treat pain associated with postherpetic neuralgia. Components of the patch; When the treatment of herpes zoster should begin.

  • FDA actions.  // Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2 

    The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.

  • Valacyclovir for herpes zoster.  // American Family Physician;12/1/1995, Vol. 52 Issue 8, p2402 

    Reports on the United States Food and Drug Administration's approval of the use of valacyclovir in treating herpes zoster. Effectiveness of the drug when instituted within 72 hours of the onset of the shingles rash; Dosing regimen.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics